RareBoost Seminar Announcement – Prof. Yağız Üresin
On May 23rd at 11:00, Prof. Yağız Üresin will give a seminar titled ” Drug development in Rare Diseases” at IBG.
Prof. Üresin has extensive experience in clinical pharmacology and conducting clinical trials. Currently, he serves as the Head of the Department of Medical Pharmacology in Istanbul University Faculty of Medicine.
We welcome your participation in Prof. Üresin’s seminar discussing the challenges and opportunities faced in the drug development process for rare diseases.
Introducing Prof. Yağız Üresin
Dr. Üresin graduated from Istanbul University Faculty of Medicine in 1986 and completed his specialization in Pharmacology in 1990. He worked at the Istanbul University Faculty of Medicine, Department of Internal Medicine Cardiology between 1987-1988, and at Sandoz Basel Human Pharmacology between 1991-93. He became a Professor in 2004, and the Head of the Department of Medical Pharmacology in 2006.
Prof. Üresin is the Chairman of the Department of Clinical Pharmacology and the Clinical Research Ethics Committee at Istanbul Faculty of Medicine, a board member of the Biotechnology and Genetic Engineering Application and Research Center at Istanbul University, the President of the Atherosclerosis Society, and a Hypertension Specialist at the European Society of Hypertension. He speaks English and German, and he has been the Erasmus Coordinator and Chairman of the Turkish German Medical Relations Commission for many years.
Prof. Üresin has conducted clinical trials in every phase, from Phase I to Phase IV studies. His professional interests include clinical research, translational science, atherosclerosis, hypertension, dyslipidemia, inflammation, and information management.
Seminar abstract
Drug development in rare diseases, particularly in the context of clinical trials, presents a unique set of challenges and opportunities. Regulatory frameworks, such as the Orphan Drug Act, have spurred advancements in this specialized area of research. However, the limited understanding and knowledge of rare diseases pose significant hurdles in both preclinical and clinical research phases. Clinical trials for rare diseases encounter difficulties in defining suitable study endpoints and identifying appropriate patient populations due to the scarcity of natural history data. The emphasis on translational research and active patient involvement underscores the necessity for innovative approaches in drug development for rare diseases. The dynamic landscape of clinical trials in rare diseases underscores the importance of tailored strategies to address the complexities inherent in developing treatments for these conditions, ultimately aiming to improve outcomes and quality of life for individuals affected by rare diseases.